On October 11, according to Gan Li Pharmaceutical, the company's self-developed and produced glycine insulin injections officially obtained marketing approval from the British Medicines and Health Products Administration to treat diabetes in adults, adolescents, and children aged 2 and above.

On October 11, according to Gan Li Pharmaceutical, the company's self-developed and produced glycine insulin injections officially obtained marketing approval from the British Medicines and Health Products Administration to treat diabetes in adults, adolescents, and children aged 2 and above.